Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Investors Demand Growth While Firm Emphasizes Efficiency

This article was originally published in The Tan Sheet

Executive Summary

Firm has largely completed its portfolio trimming and restructuring and continues to see productivity gains, but organic growth fell short of many investors' expectations in fiscal 2015, inching up 1% for the year. During a fiscal 2015 full-year earnings call July 30, analysts questioned P&G's strategy, expected timing for improvements and whether recent divestitures will have the impact the firm foresees.

You may also be interested in...



P&G Streamlining Could Cut $12 Billion Beauty Slice To Coty

Coty could growing its global beauty presence significantly by acquiring P&G's Wella and Clairol hair-care businesses, CoverGirl and Max Factor makeup lines and prestige fragrance licenses in a deal rumored to be in the works.

Lafley Back At P&G Helm As McDonald’s Tenure Ends At Four Years

Procter & Gamble turns to its former leader, previously replaced by Bob McDonald in 2009, after facing investor and analyst pressure to shake up management. Lafley’s return as CEO “provides us with new hope,” one market analyst says.

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107812

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel